Can-Fite BioPharma has declared positive Phase I/II results of CF10, used in the treatment of hepatocellular carcinoma.

The interim Phase I/II trial, which included 18 patients with hepatocellular carcinoma, proved that the drug candidate has favourable clinical efficacy.

CF102 is an agonist at the A3 adenosine receptor, which shows selective activity on diseased cells.